A spatial covariance ¹²³I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer's disease.

"Disclosure statement Dr Colloby, Dr Field, and Professor Wyper report no disclosures. Professor O'Brien has been a consultant for GE Healthcare, Lilly, Bayer Healthcare, TauRx, and Nutricia and has received honoraria for talks from GE Healthcare, Lilly, and Novartis. Dr Taylor has been a consultant of Lundbeck and received honoraria for talks from GE Healthcare and Flynn pharmaceuticals."

"The authors thank the Alzheimer's Society, the Newcastle Healthcare Charity, the Medical Research Council UK (grant number G9817682), the National Institute for Health Research (NIHR) for Public Benefit, Wellcome Trust (WT088441MA Fellowship funding John-Paul Taylor), NIHR Dementia Biomedical Research Unit at Cambridge University Hospitals NHS Foundation Trust, the University of Cambridge, The NIHR Newcastle Biomedical Research Centre in Ageing and Chronic Disease, and Biomedical Research Unit in Lewy Body Dementia based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The authors thank staff at the Regional Medical Physics Department, Department of Nuclear Medicine, Newcastle General Hospital for undertaking SPECT scanning, and all members of the clinical research team who helped with patient recruitment and assessment."